ホーム>>Signaling Pathways>> Neuroscience>> Ophthalmology>>17-trifluoromethylphenyl trinor Prostaglandin F2α methyl ester

17-trifluoromethylphenyl trinor Prostaglandin F2α methyl ester (Synonyms: 17trifluoromethylphenyl trinor PGF2α methyl ester)

カタログ番号GC41978

プロスタグランジンF2α(PGF2α)は、FP受容体を介して平滑筋収縮を引き起こし、強力な黄体退化作用を示します。

Products are for research use only. Not for human use. We do not sell to patients.

17-trifluoromethylphenyl trinor Prostaglandin F2α methyl ester 化学構造

Cas No.: 195503-20-9

サイズ 価格 在庫数 個数
1mg
$79.00
在庫あり
5mg
$354.00
在庫あり
10mg
$630.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Prostaglandin F2α (PGF2α), acting through the FP receptor, causes smooth muscle contraction and exhibits potent luteolytic activity. 17-trifluoromethylphenyl trinor PGF2α is an analog of PGF2α that shares the meta-trifluoromethyl group of travoprost with the 17-phenyl trinor modification of latanoprost. It is anticipated to be a potent and selective agonist of the FP receptor, with potential applications in glaucoma and luteolysis. 17-trifluoromethylphenyl trinor PGF2α methyl ester is a lipophilic analog of 17-trifluoromethylphenyl trinor PGF2α. Methyl esters of PGs serve as prodrugs, as they are efficiently hydrolyzed in certain tissues to generate the bioactive free acid.

レビュー

Review for 17-trifluoromethylphenyl trinor Prostaglandin F2α methyl ester

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 17-trifluoromethylphenyl trinor Prostaglandin F2α methyl ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.